Clinical Trial: A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
Study Status: Completed
Recruit Status: RECRUITING
Condition: Leukemia
Study Type: INTERVENTIONAL
Official Title: A Phase 1/2a, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety and Efficacy of GDX012 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Brief Summary:
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML).The main aims of the study are to learn how safe GDX012 is, how treatment with GDX012 is tolerated and to determine the best dose of GDX012.
Read more